General Information of Drug (ID: DMHFPRJ)

Drug Name
A-796260 Drug Info
Synonyms
895155-26-7; (1-(2-morpholinoethyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; A-796260; UNII-5N69DXA53Z; CHEMBL262865; 5N69DXA53Z; A 796260; A-796,260; ZCFHOMLAFTWDFM-UHFFFAOYSA-N; A796260; Morpholino-ethyl analogue, 32; SCHEMBL2076954; CTK8B4187; BDBM21311; MolPort-023-278-969; ZINC14975818; ANW-44204; AKOS015999103; (1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; KB-74376; AJ-65531; AS-19178; AX8228482; TC-132949; ST24020055; X5014; J3.566.431I
Indication
Disease Entry ICD 11 Status REF
Pain MG30-MG3Z Investigative [1]
Cross-matching ID
PubChem CID
11584525
CAS Number
CAS 895155-26-7
TTD Drug ID
DMHFPRJ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [2]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
KHK-6188 DMF6CTI Neuropathic pain 8E43.0 Phase 2 [5]
LY-2828360 DMO8IEZ Pain MG30-MG3Z Phase 2 [5]
APD371 DM3XT5V Crohn disease DD70 Phase 2 [6]
S-777469 DMZGNOJ Atopic dermatitis EA80 Phase 2 [7]
842166X DMOV0AP Pain MG30-MG3Z Phase 2 [8]
Beta-caryophyllene DM7583A Pain MG30-MG3Z Phase 2 [9]
Vicasinabin DMF16CU Diabetic retinopathy 9B71.0 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [11]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [3]
Orlistat DMRJSP8 Obesity 5B81 Approved [12]
SR141716A DMCO5JZ Obesity 5B81 Approved [13]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [14]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [15]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [4]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [16]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [17]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [18]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
Cannabinoid receptor 2 (CB2) TTMSFAW CNR2_HUMAN Inhibitor [1]

References

1 Indol-3-ylcycloalkyl ketones: effects of N1 substituted indole side chain variations on CB(2) cannabinoid receptor activity. J Med Chem. 2010 Jan 14;53(1):295-315.
2 Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory. Neurobiol Learn Mem. 2008 Sep;90(2):374-81.
3 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
4 Company report (Gwpharm)
5 Recent Development of CB2 Selective and Peripheral CB1/CB2 Cannabinoid Receptor Ligands. Current Medicinal Chemistry . 10/2013; 21(2).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs. 2009 Mar;14(1):165-79.
8 The agonist binding mechanism of human CB2 receptor studied by molecular dynamics simulation, free energy calculation and 3D-QSAR studies. Yao Xue Xue Bao. 2013 Sep;48(9):1436-49.
9 The cannabinoid CB1 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Eur Neuropsychopharmacol. 2014 Apr;24(4):608-20.
10 Clinical pipeline report, company report or official report of Roche
11 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
12 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
13 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
14 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
15 Clinical pipeline report, company report or official report of AstraZeneca (2009).
16 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
17 Clinical pipeline report, company report or official report of Bird Rock Bio.
18 Clinical pipeline report, company report or official report of Affimed Therapeutics.